BACKGROUND: Intravenous immunoglobulin (IVIG) is a therapeutic modality approved for the treatment of autoimmune disorders. OBJECTIVE: This review discusses how IVIG can prevent brain damage following ischemic stroke and discuss the potential mechanisms of action. METHODS: Medline and the world wide web were searched and the relevant literature was classified under the following categories: IVIG, IVIG mechanism of action, and ischemic stroke injury mechanisms. RESULTS/ CONCLUSION: Brain ischemia induces an inflammatory response that contributes to neuronal cell death. Because of its ability to block multiple molecular events, IVIG may have particularly strong neuroprotective action against ischemic brain injury. In light of the extensive clinical experience with IVIG for other indications, development of clinical trials to evaluate the use of IVIG in human stroke patients are warranted.
BACKGROUND: Intravenous immunoglobulin (IVIG) is a therapeutic modality approved for the treatment of autoimmune disorders. OBJECTIVE: This review discusses how IVIG can prevent brain damage following ischemic stroke and discuss the potential mechanisms of action. METHODS: Medline and the world wide web were searched and the relevant literature was classified under the following categories: IVIG, IVIG mechanism of action, and ischemic stroke injury mechanisms. RESULTS/ CONCLUSION: Brain ischemia induces an inflammatory response that contributes to neuronal cell death. Because of its ability to block multiple molecular events, IVIG may have particularly strong neuroprotective action against ischemic brain injury. In light of the extensive clinical experience with IVIG for other indications, development of clinical trials to evaluate the use of IVIG in humanstrokepatients are warranted.
Authors: Arieh Moussaieff; Jin Yu; Hong Zhu; Sebastiano Gattoni-Celli; Esther Shohami; Mark S Kindy Journal: Brain Res Date: 2012-01-09 Impact factor: 3.252
Authors: David Yang-Wei Fann; Yun-An Lim; Yi-Lin Cheng; Ker-Zhing Lok; Prasad Chunduri; Sang-Ha Baik; Grant R Drummond; S Thameem Dheen; Christopher G Sobey; Dong-Gyu Jo; Christopher Li-Hsian Chen; Thiruma V Arumugam Journal: Mol Neurobiol Date: 2017-01-14 Impact factor: 5.590
Authors: Ekaterina V Medvedeva; Veronika G Dmitrieva; Svetlana A Limborska; Nikolay F Myasoedov; Lyudmila V Dergunova Journal: Mol Genet Genomics Date: 2017-03-02 Impact factor: 3.291
Authors: Alexander Widiapradja; Viktor Vegh; Ker Zhing Lok; Silvia Manzanero; John Thundyil; Mathias Gelderblom; Yi-Lin Cheng; Dale Pavlovski; Sung-Chun Tang; Dong-Gyu Jo; Tim Magnus; Sic L Chan; Christopher G Sobey; David Reutens; Milan Basta; Mark P Mattson; Thiruma V Arumugam Journal: J Neurochem Date: 2012-04-27 Impact factor: 5.372
Authors: Trent M Woodruff; John Thundyil; Sung-Chun Tang; Christopher G Sobey; Stephen M Taylor; Thiruma V Arumugam Journal: Mol Neurodegener Date: 2011-01-25 Impact factor: 14.195
Authors: D Yang-Wei Fann; S Y Lee; S Manzanero; S C Tang; M Gelderblom; P Chunduri; C Bernreuther; M Glatzel; Y L Cheng; J Thundyil; A Widiapradja; K Z Lok; S L Foo; Y C Wang; Y I Li; G R Drummond; M Basta; T Magnus; D G Jo; M P Mattson; C G Sobey; T V Arumugam Journal: Cell Death Dis Date: 2013-09-05 Impact factor: 8.469
Authors: Stanley C Jordan; Nancy Reinsmoen; Alice Peng; Chih-Hung Lai; Kai Cao; Rafael Villicana; Mieko Toyoda; Joseph Kahwaji; Ashley A Vo Journal: Pediatr Nephrol Date: 2010-01-14 Impact factor: 3.714